SYLVANT

Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration has approved SYLVANT for the treatment of patients with multicentric Castleman's disease who are human immunodeficiency virus negative and human herpesvirus-8 negative.

http://ift.tt/1f85X8Q